Quality of Service Deficiency Rejected as Basis for False Claim
Client Alert | 1 min read | 01.12.02
The Second Circuit Court of Appeals has rejected allegations that a health care provider violated the False Claims Act by billing Medicare for health services deficient in quality. United States ex rel. Mikes v. Straus (Dec. 19, 2001).
Government prosecutors and qui tam relators have been increasingly creative in their use of the federal False Claims Act as a means of policing the healthcare industry. Prosecutors have gone so far as to assert that in filing a claim for payment with the government, the claimant certifies that it is operating in conformance with all laws and regulations the claimant is otherwise obligated to abide by, however unrelated to the claim submission those other legal obligations might be. Aggressive prosecutors argue that if this can be proven not to be the case, such a claim has been filed "falsely." Of particular note has been the government's recent positing that "quality of care" deficiencies may give rise to False Claims Act prosecutions.
The attached summary of the Mikes decision makes clear that the False Claims Act cannot be utilized indiscriminately as an enforcement weapon for prosecutors or relators to test a claimant's conformance with all legal obligations. In Mikes, the court specifically chides the government for seeking to use the FCA to enforce quality of care standards "best addressed by those professionals most versed in the nuances of providing adequate health care." This decision should assist significantly in redefining the fair bounds for the application of the False Claims Act in the healthcare arena.
Full case summary, provides further detail on this important False Claims case decision.
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today